{"id":965137,"date":"2026-05-20T08:03:43","date_gmt":"2026-05-20T12:03:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/"},"modified":"2026-05-20T08:03:43","modified_gmt":"2026-05-20T12:03:43","slug":"incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/","title":{"rendered":"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner&#8217;s proprietary experimental data<\/i><\/li>\n<li><i>Incyte data will be securely used to train Genesis\u2019 next-generation GEMS AI platform as part of Incyte\u2019s efforts to speed up drug development across multiple programs<\/i><\/li>\n<li><i>Genesis to receive $120M with potential for success-based milestone payments and royalties<\/i><\/li>\n<\/ul>\n<p>WILMINGTON, Del. &amp; SAN MATEO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fincyte.com%2F&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=Incyte&amp;index=1&amp;md5=6b0f7e6836cfc52e6b7f667f44983536\">Incyte<\/a> (Nasdaq:INCY) and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fgenesis.ml%2F&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=Genesis+Molecular+AI&amp;index=2&amp;md5=c1d61a04b07987cd72bde7d0edee7849\">Genesis Molecular AI<\/a> today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte. The expanded agreement is among the first major pharma-AI collaborations to power large-scale foundation model training with a partner&#8217;s proprietary experimental data.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260520680248\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260520680248\/en\/<\/a><\/p>\n<p>\nBuilding on the companies&#8217; <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20250220803826%2Fen%2FIncyte-and-Genesis-Therapeutics-Announce-Strategic-AI-focused-Research-Collaboration&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=initial+collaboration&amp;index=3&amp;md5=6eda1ed194e68d7426fc7359c1046381\">initial collaboration<\/a> announced in February 2025, the expanded agreement broadens the deployment of Genesis\u2019 AI platform, GEMS (Genesis Exploration of Molecular Space) \u2013 which includes the leading foundation models for protein-ligand structure and property prediction \u2013 across a wider variety of challenging targets in Incyte\u2019s portfolio. Incyte will also share proprietary experimental data with Genesis to enhance GEMS\u2019 capabilities.<\/p>\n<p>\n\u201cThis expanded collaboration reflects the strong results from our initial programs and Incyte\u2019s commitment to applying advanced technologies to enhance our discovery engine and accelerate the development of differentiated small molecule medicines,\u201d said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of R&amp;D. \u201cBy combining our deep expertise in drug discovery and development and our significant experimental data with Genesis&#8217; AI capabilities, we aim to more efficiently advance priority programs against high-value targets and ultimately bring important new medicines to patients.&#8221;<\/p>\n<p>\n\u201cOur partnership with Incyte reflects the exciting synergy between our AI platform and Incyte\u2019s deep expertise and capabilities in rapid experimental data generation and marks an important moment in the evolution of AI in this vertical,\u201d said Evan Feinberg, Ph.D., Founder and Chief Executive Officer of Genesis. \u201cHigh-quality proprietary data is among the most valuable inputs for advancing molecular AI, and our expanded collaboration will enable both companies and patients to benefit from an industrial-scale flywheel of AI-enabled design-make-test cycles.&#8221;<\/p>\n<p><b>Terms of the Agreement<\/b><\/p>\n<p>\nGenesis will receive total upfront consideration of $120 million, which includes an $80 million upfront cash payment and a $40 million purchase of equity in Genesis. In addition, Incyte will also provide recurring research funding to Genesis to support AI model training and inference compute workloads.<\/p>\n<p>\nThe companies will add at least five new collaboration targets selected by Incyte, and Incyte will have options to nominate additional collaboration targets over time. Incyte will have exclusive rights to develop and commercialize any collaboration products.<\/p>\n<p>\nGenesis will be eligible to receive potential preclinical and clinical development, regulatory and sales milestone payments of up to $232 million for each program contingent on the achievement of agreed upon milestones. Genesis will be eligible to receive over $1 billion if all milestones are achieved across the five initial collaboration targets, including multiple indications and major territories, provided the aggregate peak annual net sales of the five products exceed specified milestones. Additional payments totaling several billion dollars could be earned depending on the number of additional collaboration targets nominated and the achievement of related milestones. Genesis is also eligible to receive royalties on sales of any approved collaboration products.<\/p>\n<p><b>About Incyte<sup>\u00ae<\/sup><\/b><\/p>\n<p>\nIncyte is redefining what\u2019s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive pipeline of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.<\/p>\n<p>\nTo learn more, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fincyte.com&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=Incyte.com&amp;index=4&amp;md5=84d6527947ea15d732f515d90f74a621\">Incyte.com<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestor.incyte.com&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=Investor.Incyte.com&amp;index=5&amp;md5=664e107ad8d4eea1f2565f89e62975a4\">Investor.Incyte.com<\/a>. Follow us on social media: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fincyte%2F&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=d05eb70274571e04b2c3fbd404c4a74f\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FIncyte&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=X&amp;index=7&amp;md5=f6bc4332cc2a3ca97602ee1eb4da1ba5\">X<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fincyte%2F&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=Instagram&amp;index=8&amp;md5=a442c628de698fee2e707bd4dba68d77\">Instagram<\/a>.<\/p>\n<p><b>About Genesis Molecular AI<\/b><\/p>\n<p>\nGenesis Molecular AI, Inc. is pioneering foundation models for molecular AI to unlock a new era of agentic drug design and development. The company\u2019s generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20251028030745%2Fen%2FGenesis-Molecular-AI-Unveils-Pearl-a-Field-Leading-Foundation-Model-that-Achieves-Unprecedented-Performance-in-Drug-Protein-Structure-Prediction&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=Pearl&amp;index=9&amp;md5=e0ee690e892b166f45f8e21708e37843\">Pearl<\/a> for structure prediction. Genesis is backed by premier AI and life science investors, including a16z, NVIDIA, Rock Springs Capital, Menlo Ventures, T. Rowe Price, Fidelity, and Radical Ventures.<\/p>\n<p>\nGenesis is headquartered in the San Francisco Bay Area, with locations in San Diego and New York. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fgenesis.ml&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=genesis.ml&amp;index=10&amp;md5=3ea4d29c0398b913f9c2deb7f86c292c\">genesis.ml<\/a> or follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Flinkedin.com%2Fcompany%2Fgenesis-molecular-ai&amp;esheet=54538743&amp;newsitemid=20260520680248&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=11&amp;md5=4534b6aa79762550fbc28098c7ac362d\">LinkedIn<\/a>.<\/p>\n<p><b>Incyte Forward-Looking Statements<\/b><\/p>\n<p>\nExcept for the historical information set forth herein, the matters set forth in this press release, including statements regarding Incyte\u2019s expectations for its collaboration with Genesis, the potential for the collaboration to enhance Incyte\u2019s discovery engine and accelerate the development of differentiated small molecule medicines, and Incyte\u2019s expectation that the collaboration will further its aim to advance priority programs more efficiently and ultimately bring important new medicines to patients, contain predictions, estimates and other forward-looking statements.<\/p>\n<p>\nThese forward-looking statements are based on Incyte\u2018s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments or outcomes in research and development, the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development, the ability to enroll sufficient numbers of subjects in clinical trials, determinations made by regulatory authorities, Incyte\u2018s dependence on its relationships with its collaboration partners, the efficacy or safety of Incyte\u2018s products, the acceptance of Incyte\u2018s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte\u2018s reports filed with the Securities and Exchange Commission, including its annual report on Form 10-K and its report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260520680248\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260520680248\/en\/<\/a><\/span><\/p>\n<p><b><span class=\"bwuline\">Incyte Contacts<br \/>\n<\/span><\/b><br \/><b>Media<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:media@incyte.com\">media@incyte.com<\/a><\/p>\n<p><b>Investors<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:ir@incyte.com\">ir@incyte.com<\/a><\/p>\n<p><b><span class=\"bwuline\">Genesis Contacts<br \/>\n<\/span><\/b><br \/><b>Media<br \/>\n<\/b><br \/>Thermal for Genesis<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:press@genesis.ml\">press@genesis.ml<\/a><\/p>\n<p><b>Investors<br \/>\n<\/b><br \/>Carl Tilbury<br \/>\n<br \/>Vice President, Business Development<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:carl@genesis.ml\">carl@genesis.ml<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California Delaware United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Technology Research Health Technology Biotechnology Health Pharmaceutical Science Artificial Intelligence Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260520680248\/en\/2657923\/3\/Genesis_Molecular_AI_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260520680248\/en\/2810107\/3\/Incyte_Color_Logo_JPEG_2_Color_Positive.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner&#8217;s proprietary experimental data Incyte data will be securely used to train Genesis\u2019 next-generation GEMS AI platform as part of Incyte\u2019s efforts to speed up drug development across multiple programs Genesis to receive $120M with potential for success-based milestone payments and royalties WILMINGTON, Del. &amp; SAN MATEO, Calif.&#8211;(BUSINESS WIRE)&#8211;Incyte (Nasdaq:INCY) and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte. The expanded agreement is among the first major pharma-AI &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-965137","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner&#8217;s proprietary experimental data Incyte data will be securely used to train Genesis\u2019 next-generation GEMS AI platform as part of Incyte\u2019s efforts to speed up drug development across multiple programs Genesis to receive $120M with potential for success-based milestone payments and royalties WILMINGTON, Del. &amp; SAN MATEO, Calif.&#8211;(BUSINESS WIRE)&#8211;Incyte (Nasdaq:INCY) and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte. The expanded agreement is among the first major pharma-AI &hellip; Continue reading &quot;Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T12:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery\",\"datePublished\":\"2026-05-20T12:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/\"},\"wordCount\":1064,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/\",\"name\":\"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-05-20T12:03:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/","og_locale":"en_US","og_type":"article","og_title":"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery - Market Newsdesk","og_description":"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner&#8217;s proprietary experimental data Incyte data will be securely used to train Genesis\u2019 next-generation GEMS AI platform as part of Incyte\u2019s efforts to speed up drug development across multiple programs Genesis to receive $120M with potential for success-based milestone payments and royalties WILMINGTON, Del. &amp; SAN MATEO, Calif.&#8211;(BUSINESS WIRE)&#8211;Incyte (Nasdaq:INCY) and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte. The expanded agreement is among the first major pharma-AI &hellip; Continue reading \"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-20T12:03:43+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery","datePublished":"2026-05-20T12:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/"},"wordCount":1064,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/","name":"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-05-20T12:03:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520680248r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-and-genesis-expand-molecular-ai-collaboration-to-accelerate-drug-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=965137"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965137\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=965137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=965137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=965137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}